PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
The Basel-based pharmaceutical company Roche is acquiring mySugr GmbH, a mobile diabetes platform. Roche is launching its own platform for digital diabetes management, and mySugr will become an integral part of it.
The acquisition will allow Roche to expand its leading position in the area of diabetes management, said Roche in a statement. mySugr’s open platform has over 1 million users worldwide, and the two companies have already been partnering since 2014.
“We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones,” said Frank Westermann, CEO and co-founder of mySugar. The system allows diabetes patients automatically upload blood glucose data from their preferred device into the mySugr logbook app.
This function will remain in place after the acquisition, and mySugr will continue to be a separate legal entity. At the same time, it will become an integral part of Roche’s new patient-centred digital health services platform in diabetes care.
“We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes,” said Roland Diggelmann, CEO of Roche Diagnostics. “Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life.”